GlassScriptPhysician profile
Malini M Patel
NPI 1619250461
$11,211.68
in general payments reported to CMS, 2019-2025
20 companies · $2,114 in 2025
The $2,114 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,468 · 2020: $4,200 · 2021: $113 · 2022: $81.99 · 2023: $102 · 2024: $133 · 2025: $2,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,607 · Food and Beverage: $706 · Education: $36.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,606.50 |
| Food and Beverage | $706.18 |
| Education | $36.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $10,287.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $122.02 | 2021-2025 | Tagrisso, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $106.86 | 2024-2025 | Opdualag |
| Amgen INC. | $100.72 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $67.06 | 2025 | |
| Glaxosmithkline, LLC. | $61.61 | 2025 | Jemperli, Zejula, Ojjaara |
| Janssen Biotech, INC. | $58.07 | 2021-2025 | Erleada, Balversa, Akeega |
| Genentech USA, INC. | $56.95 | 2021-2025 | Phesgo |
| Gilead Sciences, INC. | $52.52 | 2024-2025 | Trodelvy |
| Pfizer INC. | $48.76 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $40.05 | 2023 | Xarelto |
| Eisai INC. | $37.50 | 2024-2025 | |
| Astellas Pharma US INC | $36.24 | 2025 | Vyloy |
| Daiichi Sankyo INC. | $31.94 | 2025 | Datroway, Enhertu |
| Incyte Corporation | $21.35 | 2025 | Monjuvi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.44 | 2025 | Keytruda, Lynparza |
| Adc Therapeutics America, INC. | $17.31 | 2025 | |
| Stemline Therapeutics INC. | $16.61 | 2023 | Orserdu |
| Lilly USA, LLC | $16.49 | 2025 | Verzenio, Jaypirca |
| Tersera Therapeutics LLC | $13.40 | 2023 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malini Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.